IMRX - Latest News
Immuneering Corporation (IMRX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $129.2M. Beta to the broader market is 0.39.
The article list below shows the most recent IMRX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent IMRX Headlines
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
globenewswire.com - Oct 2, 2026
- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer
globenewswire.com - Sep 28, 2026
- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark s
Immuneering to Present at the ESMO Congress 2026
globenewswire.com - Sep 24, 2026
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer
Squarepoint Ops LLC Has $288,000 Holdings in Immuneering Corporation $IMRX
defenseworld.net - Sep 24, 2026
Squarepoint Ops LLC decreased its position in shares of Immuneering Corporation (NASDAQ: IMRX) by 74. 5% in the undefined quarter, according to the co
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival
globenewswire.com - Sep 10, 2026
- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained wei
How News Affects IMRX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IMRX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked IMRX news questions
- What is the latest IMRX news headline?
- The most recent IMRX headline (Oct 2, 2026) is "Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the IMRX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What IMRX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual IMRX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.